XML 50 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Summary of Segment Information

The table below provides segment information about the Group:

 

 

Year Ended December 31,

 

 

 

2024

 

 

 

2023

 

 

 

2022

 

 

$000s

 

 

$000s

 

 

$000s

 

Revenue

 

 

43,258

 

 

 

31,643

 

 

 

21,655

 

Less:

 

 

 

 

 

 

 

 

 

Cost of sales

 

 

(11,810

)

 

 

(12,867

)

 

 

(13,463

)

Contracted development costs (a)

 

 

(42,902

)

 

 

(35,048

)

 

 

(24,322

)

Personnel research and development costs (b)

 

 

(20,503

)

 

 

(19,468

)

 

 

(17,187

)

Other R&D costs (c)

 

 

(4,478

)

 

 

(2,421

)

 

 

(2,041

)

General & administrative expenses

 

 

(26,884

)

 

 

(26,222

)

 

 

(25,682

)

Tax expense

 

 

(845

)

 

 

(956

)

 

 

(688

)

Other segment items (d)

 

 

18,855

 

 

 

11,111

 

 

 

11,394

 

Consolidated net loss

 

 

(45,309

)

 

 

(54,228

)

 

 

(50,334

)

 

(a)
Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.
(b)
Personnel R&D costs primarily consist of salaries and personnel-related costs for personnel performing R&D activities or managing those activities that have been out-sourced; and consultants’ costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.
(c)
Other R&D costs include associated facility costs, equipment and other overheads that are directly attributable to R&D and depreciation of capital assets used for research and development activities.
(d)
The other segment items include foreign currency gain (loss), net, benefit from R&D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.
Summary of Group's Assets and Revenues by Location

An analysis of the group’s assets and revenues by location is shown below:

 

 

U.S.A.

 

 

U.K.

 

 

Germany

 

 

Total

 

 

$000s

 

 

$000s

 

 

$000s

 

 

$000s

 

Non-current assets

 

 

 

 

 

 

 

 

 

 

 

 

As at December 31, 2023

 

 

-

 

 

 

4,467

 

 

 

11,831

 

 

 

16,298

 

As at December 31, 2024

 

 

-

 

 

 

4,103

 

 

 

11,166

 

 

 

15,269

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue analysis for the year ended December 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

Research collaboration

 

 

-

 

 

 

20,940

 

 

 

-

 

 

 

20,940

 

Royalties

 

 

-

 

 

 

-

 

 

 

715

 

 

 

715

 

 

 

-

 

 

 

20,940

 

 

 

715

 

 

 

21,655

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue analysis for the year ended December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Research collaboration

 

 

-

 

 

 

30,934

 

 

 

-

 

 

 

30,934

 

Royalties

 

 

-

 

 

 

-

 

 

 

709

 

 

 

709

 

 

 

-

 

 

 

30,934

 

 

 

709

 

 

 

31,643

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue analysis for the year ended December 31,
   2024

 

 

 

 

 

 

 

 

 

 

 

 

Research collaboration

 

 

-

 

 

 

43,114

 

 

 

-

 

 

 

43,114

 

Royalties

 

 

-

 

 

 

-

 

 

 

144

 

 

 

144

 

 

 

 

-

 

 

 

43,114

 

 

 

144

 

 

 

43,258